NMK-30652-75574
3 vaccinations
3 coded responses
24 check-ins
3 free-text entries
2 call cases
- Sex
- Female
- Age at first dose
- 36-40
- ZIP prefix
- 958 / CA
- Registered
- 2020-12-22
- Relationship
- Self
- Race
- Asian
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2020-12-19
Dose 1 — Pfizer-BioNTech
-
2020-12-22
Registered in v-safe
- 2020-12-22
- 2020-12-24
- 2020-12-25
- 2020-12-26
- 2021-01-02
-
2021-01-08
Dose 2 — Pfizer-BioNTech
- 2021-01-16
- 2021-01-22
- 2021-01-29
- 2021-02-05
-
2021-02-12
Survey response — 35 day, dose 2MedDRA: Premature labour — Feeling: Fair · Be unable to work, Be unable to do your normal daily activities, Get care from a doctor or other healthcare professional · Emergency room or emergency department visit, HospitalizationMedDRA releases: 2021-09,2023-04,2024-11 · check-in answers available
-
2021-02-12
Report sent to call center — 35 day, dose 2Be unable to work · Be unable to do your normal daily activities · Get care from a doctor or other healthcare professional1 call case(s)
- 2021-02-19
-
2021-04-10
Survey response — 3 month, dose 2MedDRA: Premature delivery, Premature labour, Premature separation of placenta — Feeling: Good · Be unable to work, Be unable to do your normal daily activities, Get care from a doctor or other healthcare professional · Emergency room or emergency department visit, HospitalizationMedDRA releases: 2021-09,2023-04,2024-11 · check-in answers available
-
2021-04-10
Report sent to call center — 3 month, dose 2Be unable to work · Be unable to do your normal daily activities · Get care from a doctor or other healthcare professional1 call case(s)
-
2021-05-07
Call successfulCompleted over the phone
-
2021-10-02
Dose 3 — Pfizer-BioNTech
- 2021-10-04
- 2021-10-05
- 2021-10-06
- 2021-10-07
- 2021-10-08
- 2021-10-09
- 2021-10-16
- 2021-10-23
- 2021-10-30
- 2021-11-06
- 2021-11-13
-
2022-01-01
Survey response — 3 month, dose 3MedDRA: Nasopharyngitis — Feeling: GoodMedDRA releases: 2024-11 · check-in answers available
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2020-12-19 | Pfizer-BioNTech | |
| 2 | 2021-01-08 | Pfizer-BioNTech | |
| 3 | 2021-10-02 | Pfizer-BioNTech | No |
Call center
| Reported | Outcome | VAERS-related outcome |
|---|---|---|
| 2021-02-12 | Successful | Completed over the phone |
| 2021-04-10 | Successful 2021-05-07 |
Completed over the phone |
Free text
Release 4
Symptoms: Preterm labor at 22 weeks
Release 7
Symptoms: Preterm labor at 22 weeks, almost lost the baby, placental abruption and delivery at 25 weeks, no risk factors
Release 10
Symptoms: Cold symptoms
Free-text releases are not linked to a specific survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Nasopharyngitis | · | · | ✓ |
| SD | Premature delivery | ✓ | ✓ | ✓ |
| SD | Premature labour | ✓ | ✓ | ✓ |
| SD | Premature separation of placenta | ✓ | ✓ | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release